Literature DB >> 19474108

Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies.

Sara M O'Rourke1, Becky Schweighardt, William G Scott, Terri Wrin, Dora P A J Fonseca, Faruk Sinangil, Phillip W Berman.   

Abstract

The identification of the determinants of sensitivity and resistance to broadly neutralizing antibodies is a high priority for human immunodeficiency virus (HIV) research. An analysis of the swarm of closely related envelope protein variants in an HIV-infected individual revealed a mutation that markedly affected sensitivity to neutralization by antibodies and antiviral entry inhibitors targeting both gp41 and gp120. This mutation mapped to the C34 helix of gp41 and disrupted an unexplored structural feature consisting of a ring of hydrogen bonds in the gp41 trimer. This mutation appeared to affect the assembly of the six-helix bundle required for virus fusion and to alter the conformational equilibria so as to favor the prehairpin intermediate conformation required for the binding of the membrane proximal external region-specific neutralizing antibodies 2F5 and 4E10 and the antiviral drug enfuvirtide (Fuzeon). The "swarm analysis" method we describe furthers our understanding of the relationships among the structure, function, and antigenicity of the HIV envelope protein and represents a new approach to the identification of vaccine antigens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474108      PMCID: PMC2708639          DOI: 10.1128/JVI.00688-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Extended knobs-into-holes packing in classical and complex coiled-coil assemblies.

Authors:  John Walshaw; Derek N Woolfson
Journal:  J Struct Biol       Date:  2003-12       Impact factor: 2.867

2.  Designing CD4 immunoadhesins for AIDS therapy.

Authors:  D J Capon; S M Chamow; J Mordenti; S A Marsters; T Gregory; H Mitsuya; R A Byrn; C Lucas; F M Wurm; J E Groopman
Journal:  Nature       Date:  1989-02-09       Impact factor: 49.962

3.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 4.  Human antibodies from combinatorial libraries.

Authors:  D R Burton; C F Barbas
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

5.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

6.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

Authors:  T Zhu; H Mo; N Wang; D S Nam; Y Cao; R A Koup; D D Ho
Journal:  Science       Date:  1993-08-27       Impact factor: 47.728

7.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

8.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

Authors:  Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

9.  Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.

Authors:  A Ashkenazi; D H Smith; S A Marsters; L Riddle; T J Gregory; D D Ho; D J Capon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more
  20 in total

1.  Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.

Authors:  Sara M O'Rourke; Becky Schweighardt; Pham Phung; Kathryn A Mesa; Aaron L Vollrath; Gwen P Tatsuno; Briana To; Faruk Sinangil; Kay Limoli; Terri Wrin; Phillip W Berman
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

2.  Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function.

Authors:  Hanh T Nguyen; Nirmin Alsahafi; Andrés Finzi; Joseph G Sodroski
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

3.  Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James E Robinson; Mary Barnes; Cristian Apetrei; James M Binley
Journal:  Virology       Date:  2014-05       Impact factor: 3.616

4.  Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope.

Authors:  Leslie Goo; Caitlin Milligan; Cassandra A Simonich; Ruth Nduati; Julie Overbaugh
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

5.  Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.

Authors:  Jacklyn Johnson; Yinjie Zhai; Hamid Salimi; Nicole Espy; Noah Eichelberger; Orlando DeLeon; Yunxia O'Malley; Joel Courter; Amos B Smith; Navid Madani; Joseph Sodroski; Hillel Haim
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

6.  A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.

Authors:  Rajesh Ringe; Deepak Sharma; Susan Zolla-Pazner; Sanjay Phogat; Arun Risbud; Madhuri Thakar; Ramesh Paranjape; Jayanta Bhattacharya
Journal:  Virology       Date:  2011-08-17       Impact factor: 3.616

7.  Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.

Authors:  Sara M O'Rourke; Becky Schweighardt; Pham Phung; Dora P A J Fonseca; Karianne Terry; Terri Wrin; Faruk Sinangil; Phillip W Berman
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

8.  Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.

Authors:  S Gnanakaran; Marcus G Daniels; Tanmoy Bhattacharya; Alan S Lapedes; Anurag Sethi; Ming Li; Haili Tang; Kelli Greene; Hongmei Gao; Barton F Haynes; Myron S Cohen; George M Shaw; Michael S Seaman; Amit Kumar; Feng Gao; David C Montefiori; Bette Korber
Journal:  PLoS Comput Biol       Date:  2010-10-07       Impact factor: 4.475

9.  Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.

Authors:  Javier F Morales; Bin Yu; Gerardo Perez; Kathryn A Mesa; David L Alexander; Phillip W Berman
Journal:  Mol Immunol       Date:  2016-07-21       Impact factor: 4.407

10.  HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.

Authors:  Javier F Morales; Trevor J Morin; Bin Yu; Gwen P Tatsuno; Sara M O'Rourke; Richard Theolis; Kathryn A Mesa; Phillip W Berman
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.